COMPARISON
Exenatide vs Liraglutide
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Exenatide is authorised or registered in 5 and Liraglutide in 10 of the 10 registers read. Exenatide: highest phase Phase 2. Liraglutide: highest phase Phase 4 (after approval). 40 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Exenatide | Liraglutide | |
|---|---|---|
| Registered trials differs | 383 clinicaltrials.gov · 2026-10-03 | 518 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Byetta openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Liraglutide openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Withdrawn ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for exenatide | 2009-06-30 ema · 2026-10-03 |
| EU withdrawn on differs | 2024-11-20 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for liraglutide |
| ATC code differs | A10BJ01 ema · 2026-10-03 | A10BJ02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Exenatide | placebo | Liraglutide | placebo |
|---|---|---|---|---|
| Headache | 1.9% | 1.3% | 8.3% | 5.9% |
| Constipation | 0.8% | 0.3% | 8.8% | 3.1% |
| Dyspepsia | 0.8% | 0.3% | 5.3% | 1.3% |
| Non-cardiac chest pain | 1.1% | 1.0% | - | - |
| Osteoarthritis | 0.9% | 1.0% | - | - |
| Dizziness | 0.8% | 0.4% | - | - |
| Chronic obstructive pulmonary disease | 0.7% | 0.7% | - | - |
| Fatigue | 0.6% | 0.1% | - | - |
| Back pain | 0.5% | 0.6% | - | - |
| Sinusitis | 0.5% | 0.2% | - | - |
| Nausea | - | - | 26.4% | 7.4% |
| Diarrhoea | - | - | 13.1% | 6.1% |
| Nasopharyngitis | - | - | 12.4% | 9.3% |
| Vomiting | - | - | 9.0% | 2.1% |
| Hypoglycaemia | - | - | 8.7% | 3.3% |
| Decreased appetite | - | - | 6.6% | 1.2% |
| Upper respiratory tract infection | - | - | 6.0% | 4.7% |
Trial register Exenatide: 24 placebo-controlled trials; Liraglutide: 42. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Exenatide side effects · Liraglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Exenatide | Liraglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Withdrawn | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
40 registered trials include both
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
|---|---|
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists RECRUITING · updated 2026-07-24 |
| NCT07309094 | Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD RECRUITING · updated 2025-12-30 |
| NCT05073692 | Comparison of Type 2 Diabetes Pharmacotherapy Regimens COMPLETED · updated 2025-11-21 |
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Rea ACTIVE_NOT_RECRUITING · updated 2025-09-23 |
| NCT03492580 | A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants COMPLETED · updated 2025-06-25 |
| NCT06449235 | Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh UNKNOWN · updated 2024-07-16 |
| NCT05136287 | SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULT COMPLETED · updated 2024-02-28 |
| NCT03151005 | The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS COMPLETED · updated 2023-12-04 |
| NCT05161429 | BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes UNKNOWN · updated 2023-06-22 |
| NCT01511393 | An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) ENROLLING_BY_INVITATION · updated 2023-06-13 |
| NCT02244164 | Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. TERMINATED · updated 2023-02-16 |
| NCT02787551 | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FR COMPLETED · updated 2022-03-25 |
| NCT03671733 | Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients UNKNOWN · updated 2021-04-09 |
| NCT04027023 | Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus UNKNOWN · updated 2021-04-01 |
| NCT01724060 | Effects of Obesity Treatments on Food Preferences and Metabolism COMPLETED · updated 2020-03-31 |
| NCT04184947 | Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists COMPLETED · updated 2020-03-11 |
| NCT03804411 | Prognostic Predictors of Response to Hypoglycemic Therapy UNKNOWN · updated 2020-02-10 |
| NCT02072096 | A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) TERMINATED · updated 2019-10-09 |
| NCT03959865 | GLP-1 REceptor Agonists and Real World EvIdeNce UNKNOWN · updated 2019-05-22 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.